Confidence in Dendreon ON Call

From questions about insurance coverage to patient financial assistance, Dendreon ON Call provides comprehensive support for PROVENGE therapy.

Rapid and Comprehensive Benefits Verification

Dendreon ON Call provides your practice with a dedicated case manager to:
  • Complete enrollment, benefits verification, and patient assistance eligibility checks within 48 hours*
  • Conduct an insurance verification to confirm each patient’s coverage and out-of-pocket costs
  • Determine coverage for government-insured, commercially insured, or uninsured patients
  • Initiate the patient financial assistance process for uninsured patients
  • Contact independent foundations for patients who may need financial or treatment-related travel assistance

*Missing information may delay the 48-hour turnaround.

Commitment to Patients With Limited Financial Resources

  • PROvide—Patient assistance program for patients with commercial insurance. PROvide supports eligible patients by covering any combination of cost—co-pays, co-insurance, or deductible costs—to a maximum of $6000 over the 3 PROVENGE treatments. Dendreon ON Call will verify copay assistance quickly for your patients
  • Co-pay assistance for patients with Medicare—Help with co-pays, co-insurance, and deductible costs for eligible patients
  • Support for patients without coverage for PROVENGE—Eligible patients may be able to get PROVENGE free of cost through the PROVENGE Uninsured Patient Program
  • Travel cost assistance—Help with treatment-related travel costs for eligible patients
Learn More About Treatment Scheduling

Practice Resources

INDICATION

PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia. Closely monitor patients with cardiac or pulmonary conditions.

Thromboembolic events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is intended solely for autologous use and is not tested for transmissible infectious diseases.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.

Full Prescribing Information